At JUVIA, we believe better gut health begins with understanding what reaches the colon and how the microbiome responds. For more than a decade, our research programme has explored a simple but important idea: supporting the digestion of complex food components earlier in the digestive process may help create a more favourable environment further downstream.
This scientific journey began with research into gut fermentation in horses and has progressed through animal mechanism studies, human microbiome research, a constipation pilot and the ongoing FREEDOM study in people with irritable bowel syndrome, known as IBS, and suspected small intestinal bacterial overgrowth, known as SIBO.
The results so far are encouraging. They suggest that JUVIA can influence the gut microbial community, enrich bacteria associated with beneficial short chain fatty acid production and support improvements in constipation, bloating and abdominal discomfort. The FREEDOM study is now helping us investigate these effects in greater detail, including changes in hydrogen and methane production.
What is JUVIA and how does it work?
JUVIA is an enzyme rich malt extract made from carefully malted barley. It naturally contains eight active digestive enzymes: protease, lipase, amylase, fructanase, cellulase, xylanase, beta glucanase and phytase. It also provides naturally occurring B vitamins, polyphenols and malt derived compounds.
JUVIA is not a probiotic because it does not introduce live microorganisms. It is not a fibre supplement and it is not a conventional prebiotic. Instead, its enzymes help break down a broad range of food components, including complex carbohydrates, before they reach the colon.
This matters because food that is not fully digested earlier in the gut can become substrate for fermentation by colonic microbes. For some people, this may contribute to excessive gas, altered bowel habits, bloating and abdominal pain. By changing the material available to the microbiome, JUVIA may help favour a more balanced pattern of fermentation.
Our working scientific model has three stages. First, JUVIA supports upstream digestion. Second, this changes substrate delivery to the colon and may enrich saccharolytic bacteria, which specialise in breaking down carbohydrates. Third, these bacteria can produce short chain fatty acids, including butyrate, which plays an important role in supporting the intestinal barrier.
What did the Australian IBS study find?
In 2022, a double blind crossover study involving 36 participants with IBS investigated the effects of JUVIA on the gut microbiome. Although the primary symptom endpoint was not reached, the microbiome findings were statistically significant and aligned closely with the proposed mechanism.
Researchers observed significant changes in alpha diversity and beta diversity, two measures used to understand the composition and structure of microbial communities. The study also found a 1.80 log fold enrichment of Faecalibacterium prausnitzii.
Faecalibacterium prausnitzii is widely regarded as an important butyrate producing bacterium. Butyrate helps nourish cells lining the colon and supports intestinal barrier function. Its enrichment was particularly relevant because it was one of the bacterial groups our scientific model predicted would respond.
The study also identified enrichment of Prevotella, Bacteroides, Agathobacter and Ruminococcus. These are saccharolytic or short chain fatty acid producing taxa. Together, these findings suggest that JUVIA may remodel the gut microbiome in a direction associated with more favourable carbohydrate fermentation.
What did the constipation pilot show?
A separate open label pilot conducted by the Functional Gut Clinic examined JUVIA in people experiencing constipation. Fifteen participants completed four weeks of supplementation, taking 15 ml twice daily.
The results showed a statistically significant improvement in KESS constipation scores, a recognised questionnaire used to assess constipation severity. Stool consistency also improved significantly. Participants additionally reported significant improvements in bloating and abdominal pain.
This was a small pilot without a placebo control, so the findings should be interpreted with appropriate caution. However, the consistency across constipation severity, stool form and digestive symptoms provided a useful clinical signal and helped shape the next phase of JUVIA research.
Importantly, no serious adverse events were reported in this study. Across completed research and wider customer use, JUVIA has maintained a reassuring safety profile.
The FREEDOM study
The FREEDOM study is designed to explore how JUVIA may affect symptoms, breath gases and fermentation patterns in people with IBS and SIBO. The study plans to include 50 participants. Each participant completes daily IBS Symptom Severity Score tracking, home hydrogen and methane monitoring, and lactulose breath testing before and after a three week JUVIA intervention.
The early findings are preliminary because only a small number of participants have completed the programme. Nevertheless, the first results provide several signals worth investigating as recruitment continues.
Four of the first five participants showed a significant improvement in IBS symptom scores after taking JUVIA. Among the first three participants who met the baseline criteria for intestinal methanogen overgrowth, all three experienced clinical improvement.
Two early cases also showed substantial reductions in methane during lactulose breath testing. One participant recorded a 49 per cent reduction, from 35.1 parts per million before JUVIA to 17.9 parts per million afterwards. Another recorded a 99 per cent reduction, from 17.5 to 0.1 parts per million.
Methane is especially relevant to constipation because higher intestinal methane levels have been associated with slower gut transit. These preliminary results may therefore help explain why JUVIA appears particularly promising for people with methane positive constipation or constipation predominant IBS. However, the FREEDOM study remains ongoing, and larger participant numbers are needed before firm conclusions can be drawn.
What continuous breath monitoring may reveal
FREEDOM is also collecting information about what participants eat and the gases their gut produces afterwards. Across the first five participants, researchers analysed 1,018 paired food and breath events.
In this early dataset, sugary foods and alcoholic drinks produced the largest hydrogen and methane responses. Foods rich in fermentable carbohydrates produced the next largest responses, while dairy was associated with the smallest hydrogen response of the categories examined.
These observations are exploratory, but they highlight an important point: breath gas production can vary considerably according to recent food intake. A single clinic based breath test offers a controlled snapshot, whereas repeated monitoring at home can show how fermentation changes during everyday life.
Who might benefit most from JUVIA?
The evidence does not suggest that every person with IBS will respond in the same way. Our current findings point most strongly towards people with a malfermentation pattern, particularly those with chronic constipation, constipation predominant IBS, mixed pattern IBS or methane levels consistent with intestinal methanogen overgrowth.
JUVIA is taken with meals so its enzymes are present when food enters the digestive system. Current study protocols use 10 to 15 ml with meals, usually three times daily. It can be taken from a spoon or mixed into a cold drink. It should not be added to hot drinks because heat can affect enzyme activity.
Building a clearer picture of digestive health
The JUVIA research programme is steadily building a clearer picture of how enzyme supported digestion may influence the gut microbiome and digestive symptoms. The Australian study demonstrated significant microbiome remodelling. The constipation pilot identified improvements in constipation, stool consistency, bloating and pain. Early FREEDOM results now suggest potential benefits for methane positive participants, alongside meaningful reductions in symptom scores.
We are excited by these findings, but we remain committed to responsible scientific communication. Early signals are not final proof, and ongoing recruitment will allow us to test whether these patterns hold across a larger and more diverse group.
For JUVIA, the goal is not simply to suppress symptoms. It is to understand the digestive environment that contributes to them and to support a healthier pattern of fermentation from the start. As the FREEDOM study progresses, we look forward to sharing further results and continuing the conversation about enzymes, the microbiome and personalised gut health research.